Using in vitro, in vivo, and computational methods to find drugs and drug targets for bacterial, viral, and parasitic diseases 

Technology Overview

Infectious diseases are a major cause of global illness and death. Malaria parasites kill more than 400,000 people a year and children are particularly susceptible. Dr. Alexis Kaushansky studies host-pathogen interactions in diseases caused by parasites, bacteria, and viruses. Her goal is to identify factors in human host cells that are required by pathogens and are thus potential therapeutic targets. A host-based approach has the potential to identify pathways and factors involved in the infections of multiple pathogens, allowing for the development of drugs that are effective against multiple diseases.  In addition, this strategy may reduce the development of drug-resistant pathogens.

Alexis KaushanskyDr. Alexis Kaushansky

Dr. Kaushansky’s group has, for example, discovered that some cancer drugs are also potent antimalarials because of overlap between the signaling pathways involved in carcinogenesis and in early, liver-stage malarial infection. The researchers performed in vitro tests for antimalarial effects on a small number of kinase inhibitor compounds, including some in clinical trials and some already approved for cancer treatment. Applying a computational method to the resulting data as well as to public datasets on human kinases, they were able to predict with 80% success other kinase inhibitors that can block malaria infection.

Dr. Kaushansky’s group also applied a machine-learning algorithm to their own and public data to identify human kinases involved in liver-stage malaria infection that could be new drug targets. This combined experimental-computational approach is applicable to host-based drug discovery for other diseases and could inform efficient compound selection and drug design.

Dr. Kaushansky has expertise in proteomics for drug discovery including the use of protein microarrays that require only picoliter samples to measure protein levels and detect post-translational modifications. Using this method, her team was able to show that levels of oncogenes and tumor suppressors are altered in infected cells in similar manners to their alterations in tumors. This observation led to the finding that multiple classes of drugs, including Bcl-2 inhibitors, a class of molecules that includes FDA-approved cancer drugs, have strong antimalarial effects. The Kaushansky group has expertise in infectious disease experiments with animal models and access to state-of-the-art insectaries for cultivating the mosquitoes that transmit malaria parasites to rodents and humans.

Stage of Development

  • Pre-clinical in vitro
  • Pre-clinical in vivo

Partnering Opportunities

  • Sponsored research agreement
  • Tissue sample access
  • Target identification
  • Drug screening
  • Insectaries and mouse models

Publications

  1. Glennon EKK, Dankwa S, Smith JD, Kaushansky A. Opportunities for host-targeted therapies for malaria. Trends Parasit. 2018; 34:843-860.
  2. Arang N, Kain HS, Glennon EK, Bello T, Dudgeon DR, … Kaushansky A. Identifying host regulators and inhibitors of liver stage malaria infection using kinase activity profiles. Nature Communications. 2017: 1232.
  3. Douglass AN, Kain HS, Abdullahi M, Arang N, Austin LS, ... Kaushansky A. Host-based prophylaxis successfully targets liver stage malaria parasites. Mol Ther. 2015; 23: 857-865.

Learn More

To learn more about partnering with Seattle Children’s Research Institute on this or other projects, please contact:

Dr. Elizabeth Aylward, Director 
Office of Science-Industry Partnerships 
Seattle Children’s Research Institute 
818 Stewart Street, Suite 603
Seattle, WA 98101
Email
206-884-1065